Key Developments: NuVasive Inc (NUVA.O)
22.57USD
22 May 2013
$-0.57 (-2.46%)
$23.14
$23.12
$23.55
$22.42
376,912
406,373
$25.99
$12.35
Latest Key Developments (Source: Significant Developments)
NuVasive Inc Announces Acquisition of ANC LLC
NuVasive Inc announced the acquisition of ANC, LLC, a spine implant manufacturer based in Dayton, Ohio. In total consideration for ANC, NuVasive will pay approximately $4.5 million. No debt will be assumed in the deal. Full Article
NuVasive Inc Announces Acquisition of ANC LLC
NuVasive Inc announced the acquisition of ANC, LLC, a spine implant manufacturer based in Dayton, Ohio. In total consideration for ANC, NuVasive will pay approximately $4.5 million. No debt will be assumed in the deal. Full Article
NuVasive Inc Reaffirms FY 2013 Guidance
NuVasive Inc announced that for fiscal 2013, it expects revenue of approximately $655 million, unchanged from prior guidance, GAAP EPS of approximately $0.02, compared to $0.07 previously and Non-GAAP EPS of approximately $1.00, unchanged from prior guidance. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $656 million and EPS of $1.00 for fiscal 2013. Full Article
NuVasive Inc Reaffirms FY 2013 Revenue Guidance; Issues FY 2013 EPS Guidance Above Analysts' Estimates
NuVasive Inc announced that for fiscal 2013, it expects revenue of approximately $655 million, GAAP EPS of approximately $0.07 and Non-GAAP EPS of approximately $1.00. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $647 million and EPS of $0.90 for fiscal 2013. Full Article
World-renowned Orthopedic Surgeon Sues NuVasive Inc For Breach Of Contract
Andrew Cappuccino, M.D., a world-renowned orthopedic surgeon based in Buffalo, announced that it has filed a lawsuit in U.S. District Federal Court, Southern District of California, accusing NuVasive Inc of breach of contract. In a civil complaint filed, Dr. Cappuccino charges NuVasive, a Delaware corporation, with principal offices in San Diego, with failure to pay a $660,000 tied to Federal Drug Administration (FDA) approval of a medical device. The device, used in spinal procedures, was developed by Cervitech, Inc., a company in which Dr. Cappuccino was a prime investor and which was acquired by NuVasive. Under terms of the share-purchase agreement, Dr. Cappuccino and his fellow Cervitech inventors were to receive payments within 30 days of FDA approval of the Cervitech-developed device. That approval was granted on October 26, and all other former Cervitech shareholders were paid with the exception of Dr. Cappuccino. Full Article
NuVasive Inc Issues FY 2013 Revenue Guidance Above Analysts' Estimates-Conference Call
NuVasive Inc announced that for fiscal 2013, it expects revenue to approximate $655 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $640 million for fiscal 2013. Full Article
NuVasive Inc Announces First Patient In United States Treated With PCM Cervical Disc Following FDA Approval
NuVasive Inc announced that Paul Sawin, M.D., performed the first PCM Cervical Disc surgery on a patient in Orlando, Florida, Surgeon proctors, who will instruct upcoming training courses, have started scheduling surgeries that the new device is available. Surgeon demand for training is strong with courses scheduled to begin next month. NuVasive received FDA approval for the PCM Cervical Disc in October 2012 after completion of a prospective, multicenter randomized investigational device exemption (IDE) clinical trial. The novel device is being provided to patients and surgeons in the United States as an innovative option to preserve motion in the cervical spine instead of a traditional, motion-eliminating fusion procedure. Full Article
NuVasive Inc Issues Q3 2012 Revenue Guidance-Conference Call
NuVasive Inc announced that for the third quarter of 2012, it expects revenue of approximately $147 million. Full Article
NuVasive, Inc. Raises FY 2012 Guidance
NuVasive, Inc. announced that for fiscal 2012, it expects revenue of approximately $625 million; up from previous guidance of approximately $615 million, GAAP EPS of approximately $0.16; up from previous guidance of approximately $0.09 and non-GAAP EPS of approximately $0.97; up from previous guidance of approximately $0.93. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $623 million and EPS of $0.95 for fiscal 2012. Full Article
NuVasive, Inc. Revises FY 2012 Guidance To A Range In Line With Analysts' Estimates-Conference Call
NuVasive, Inc. announced it is guiding to $615 million revenues and non-GAAP EPS of $0.20, and on track for a mid-$0.90 non-GAAP EPS for fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $622 million and EPS of $0.95 for fiscal 2012. Full Article
BRIEF-NuVasive jumps in premarket after revenue outlook
NEW YORK, Jan 9 - NuVasive Inc : * Jumps 12.8 percent to $17.78 in premarket after revenue outlook
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
